3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Interventions
Temozolomide
45
Radiotherapy
17
Magnetic Resonance Spectroscopy
17
Specimen Handling
14
Bevacizumab
12
pembrolizumab
11
Lomustine
9
Radiation
8
fludarabine
7
Cyclophosphamide
7
atezolizumab
4
Biopsy
4
olaparib
3
Transurethral Resection of Bladder
3
Surgical Procedures, Operative
3
Nivolumab
3
Leukapheresis
3
D2C7-(scdsFv)-PE38KDEL
3
Blood Specimen Collection
3
Aminolevulinic Acid
3
regorafenib
2
fluciclovine F-18
2
contrast agent BR1
2
antisecretory factor
2
abemaciclib
2
Restraint, Physical
2
Re-Irradiation
2
Radiation Dose Hypofractionation
2
Palliative Care
2
Oncolytic Virotherapy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Glioblastoma
×
Interleukin-15
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled